Previous Article | Next Article 
Infection and Immunity, March 2001, p. 1469-1476, Vol. 69, No. 3
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.3.1469-1476.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Human Lactoferrin and Peptides Derived from Its N
Terminus Are Highly Effective against Infections with
Antibiotic-Resistant Bacteria
P. H.
Nibbering,1,*
E.
Ravensbergen,1
M. M.
Welling,2
L. A.
van
Berkel,1
P. H. C.
van Berkel,3
E. K. J.
Pauwels,2 and
J. H.
Nuijens3
Department of Infectious
Diseases1 and Department of Radiology,
Division of Nuclear Medicine,2 Leiden University
Medical Center, and Pharming Technologies
B.V.,3 Leiden, The Netherlands
Received 20 September 2000/Returned for modification 13 October
2000/Accepted 27 November 2000
 |
ABSTRACT |
Since human lactoferrin (hLF) binds to bacterial products through
its highly positively charged N terminus, we investigated which of the
two cationic domains is involved in its bactericidal activity. The
results revealed that hLF lacking the first three residues
(hLF
3N) was less efficient than hLF in killing of
antibiotic-resistant Staphylococcus aureus, Listeria
monocytogenes, and Klebsiella pneumoniae. Both hLF
preparations failed to kill Escherichia coli O54. In
addition, hLF
3N was less effective than hLF in reducing
the number of viable bacteria in mice infected with
antibiotic-resistant S. aureus and K. pneumoniae. Studies with synthetic peptides corresponding to the
first 11 N-terminal amino acids, designated hLF(1-11), and fragments
thereof demonstrated that peptides lacking the first three N-terminal
residues are less effective than hLF(1-11) in killing of bacteria.
Furthermore, a peptide corresponding to residues 21 to 31, which
comprises the second cationic domain, was less effective than
hLF(1-11) in killing of bacteria in vitro and in mice having an
infection with antibiotic-resistant S. aureus or K. pneumoniae. Using fluorescent probes, we found that bactericidal hLF peptides, but not nonbactericidal peptides, caused an increase of
the membrane permeability. In addition, hLF killed the various bacteria, most probably by inducing intracellular changes in these bacteria without affecting the membrane permeability. Together, hLF and
peptides derived from its N terminus are highly effective against
infections with antibiotic-resistant S. aureus and K. pneumoniae, and the first two arginines play an essential role in
this activity.
 |
INTRODUCTION |
Human lactoferrin (hLF) is a major
component of the nonspecific defense of mucosal surfaces and
neutrophils and is active against a variety of pathogens (reviewed in
references 21 and 26). This protein displays antimicrobial
properties against gram-positive and gram-negative bacteria by limiting
the availability of environmental iron (2). However, since
iron-saturated hLF is also able to kill certain bacteria
(7), mechanisms other than iron depletion apparently are
involved in the antibacterial activity of LF. Recent studies have
indicated that peptides obtained after enzymatic hydrolysis of hLF
(1, 22, 37) and bovine LF (bLF) (5, 12, 30)
are much more effective in killing bacteria than is the intact protein.
Amino acid sequence analysis revealed that these antimicrobial peptides
comprised (parts of) the N-terminal residues 1 to 47 of hLF (1,
37) or 1 to 48 of bLF (5, 12). Since most natural
antimicrobial peptides are cationic (18), it is likely
that the N-terminal cationic domains of hLF and bLF play an essential
role in their bactericidal activity. hLF contains two N-terminal
cationic domains, i.e., RRRR (residues 2 to 5) and RKVR (residues 28 to
31), whereas the bactericidal domain of bLF comprises residues 17 to 42 (12, 30). It has been reported that peptides of bLF origin
(12) as well as synthetic peptides that include the second
cationic domain of hLF (3) show antibacterial activity
resulting from depolarization of the membrane, increased membrane
permeability, and metabolic injury. Moreover, some controversy exists
as to whether hLF binds to bacterial products, such as endotoxin and glycosaminoglycans, through its first (17, 32, 38) or
second (6, 36) cationic domain. Based on these
considerations, the present study was undertaken to determine whether
the first and/or second cationic domain of natural hLF is important for
its antibacterial activity and to delineate the essential N-terminal residues.
 |
MATERIALS AND METHODS |
LF and synthetic peptides.
Natural hLF (77,000 Da) was
purified from fresh milk of a single donor by cationic exchange
chromatography using S-Sepharose (32). The N terminus of
this protein was intact, as determined by N-terminal analytical Mono-S
chromatography and N-terminal Edman degradation and sequencing. hLF,
which was free of contamination with endotoxin and human lysozyme
(15) and had been purified by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis, was dialyzed against saline
and stored at
70°C at concentrations of approximately 20 mg/ml. An
hLF variant lacking the first three N-terminal residues (GRR), referred
to below as hLF
3N, was isolated from natural hLF treated
with trypsin as described previously (1). As a control,
bovine serum albumin (Sigma Chemical Co., St. Louis, Mo.) was applied
instead of hLF or hLF
3N. Synthetic peptides corresponding
to residues 1 to 11 of hLF (GRRRRSVQWCA, 1,494 Da), referred to below
as hLF(1-11), and fragments thereof and a peptide corresponding to
residues 21 to 31 of hLF (FQWQRNMRKVR, 1,567 Da), referred to below
as hLF(21-31), were prepared and purified as described previously
(4). The purity of the synthetic peptides usually exceeded
88%, as determined by reverse-phase high-performance liquid
chromatography. Stocks of synthetic peptides at 1 mM in 5% (vol/vol)
acetic acid (pH < 6.0) were stored at
20°C and dried in a
Speed-Vac (Savant Instruments Inc., Farmingdale, N.Y.) immediately
before use. As controls, we applied synthetically prepared protegrin-1
(RGGRLCYCRRRFCVCVVGR, 2,161 Da), a defensin-like molecule
with broad-spectrum antimicrobial activity that had been isolated from
pig leukocytes (14, 25), as a positive control and peptide
4 (RPVVSTQLLNGSLAEEEVV, 2,171 Da), part of the gp120 protein
from human immunodeficiency virus type 1, as a negative control.
Bacteria.
Antibiotic-resistant Staphylococcus
aureus strain 2141, a clinical isolate (Department of Infectious
Diseases, Leiden University Medical Center [LUMC]), was highly
resistant to methicillin (MIC, >256 mg/liter), cloxacillin (MIC, >256
mg/liter), penicillin (MIC, >0.25 mg/liter), gentamicin and netilmycin
(MIC of both antibiotics >8 mg/liter), erythromycin (MIC, >2
mg/liter), and tetracycline (MIC, >4 mg/liter) and displayed limited
sensitivity (MIC, <2 mg/liter) to teicoplanin and rifampin.
Listeria monocytogenes strain EGD, Klebsiella
pneumoniae ATCC 43816, and Escherichia coli O54 were
purchased from the American Type Culture Collection (Rockville, Md.).
Antibiotic-resistant S. aureus, K. pneumoniae, and E. coli were cultured overnight in nutrient broth (Oxoid, Basingstoke, United Kingdom) at 37°C, diluted in tryptase soya broth
(Oxoid), and cultured for an additional 2 h in a shaking water
bath at 37°C. L. monocytogenes was cultured overnight in brain heart infusion broth (Oxoid) at 37°C, diluted, and cultured for
an additional 2 h in a shaking water bath at 37°C.
Assay for antibacterial activity of lactoferrins and related
peptides.
An in vitro assay was used to assess the antibacterial
activity of hLF and related peptides. In short, bacteria were washed with phosphate-buffered saline (PBS) (pH 7.4) and diluted to
approximately 2 × 106 CFU/ml of PBS (pH 6.0)
(7) supplemented with 0.1% (vol/vol) Tween 20 (hereafter
designated PBS-Tw). We added this detergent to PBS to reduce the
binding of hLF to the test tube, since preliminary experiments
indicated that assessment of the bactericidal activity of this protein
in the presence of Tween 20 is more reliable. Equal volumes of this
bacterial suspension and PBS-Tw containing various concentrations of
hLF or related peptides were mixed. At various intervals (range, 0 to
4 h) after incubation at 37°C, the number of viable bacteria was
determined microbiologically. Bovine serum albumin (Sigma) or no
peptide was included as the negative control; protegrin served as the
positive control. The detection limit was 4,000 CFU.
Assay for membrane permeability.
Antimicrobial peptides may
cause bacterial cell death by inducing an increase in membrane
permeability (24, 29); therefore, we monitored changes in
the membrane permeability of bacteria on exposure to hLF,
hLF
3N, and related peptides by using propidium iodide
(PI; Sigma) staining and fluorescence-activated cell sorter (FACS)
analysis (3, 19). Stock solutions of PI (1 mg/ml of
deionized water) were prepared. Approximately 2 × 106
bacteria/ml of PBS-Tw were incubated for various intervals at 37°C,
washed, incubated for 5 min with 1 µg of PI/ml (final concentration) and then analyzed with a FACScan instrument (Becton & Dickinson, San
Jose, Calif.) equipped with a argon laser at 488 nm. The
photomultiplier voltages were routinely set at 500 V for PI
fluorescence intensity in the second channel. Data acquisition and
analysis were controlled using Lysis II software.
Assay for nonspecific esterase activity.
An increase in
membrane permeability may not be the prime reason for bacterial cell
death caused by hLF; therefore, we investigated the effects of hLF,
hLF
3N and related peptides in bacteria on the
intracellular nonspecific esterase activity of bacteria assessed using
5-sulfofluorescein diacetate (SFDA) (Molecular Probes, Leiden, The
Netherlands) and FACS analysis (31). For this purposes, a
stock solution of SFDA (1 mg/ml of ethanol) was prepared. Approximately
2 × 106 CFU of bacteria/ml of PBS-Tw was incubated
with several concentrations of hLF, hLF
3N, and
hLF-related peptides for various intervals at 37°C, washed, incubated
with 100 µM SFDA/ml (final ethanol concentration, 20% [vol/vol])
for 20 min at room temperature in the dark, and then analyzed with a
FACScan instrument (excitation, 488 nm; emission, 700 nm)
(31) using the photomultiplier voltage of the first channel set at 700 V.
Labeling of LF and related peptides with
99mtechnetium.
Lactoferrins and related peptides were
labeled with 99mtechnetium (99mTc) as described
previously (23, 34, 35). Briefly, 10 µl of a peptide
solution (1 mg/ml of acetic acid) was added to 4 µl of an aseptic
solution of 0.5 mg of stannous pyrophosphate/ml (Department of Clinical
Pharmacy and Toxicology, LUMC). Immediately thereafter, 2 µl of a
solution of 10 mg of KBH4 (crystalline; Sigma) per ml of
0.1 M NaOH was added. After addition of 0.1 ml of sodium
[99mTc]pertechnetate solution (200 MBq/ml; Mallinckrodt
Medical BV, Petten, The Netherlands), the mixture was gently stirred at
ambient temperature for 30 min and was then ready for use. Quality
control of the labeling was performed by reverse-phase high-performance liquid chromatography analysis using a Sep-Pak C18 cartridge (Waters, Milford, Mass.) in 20 ml of 0.01 M acetic acid. After rinsing with 20 ml of 0.01 M acetic acid, proteins and peptides were eluted with 2 ml
of methanol (Sigma). Labeling yields amounted to 88 to 95%. The
precise binding site of the radionuclide on hLF and related peptides is
not known yet. However, this labeling procedure is very mild to these
proteins and peptides since it does not affect their biological
activity (23, 34, 35), cationicity (as determined by
mono-S chromatography) (32), or binding to receptors (R. Rossin, M. C. Giron, D. Blok, R. Feitsma, U. Mazzi, and E. K. J. Pauwels, Abstract, Nucl. Med. Commun.,
21:593-594, 2000).
Experimental thigh muscle infections.
All animal studies
were done in compliance with the Leiden Experimental Animal Committee
and Dutch laws related to the conduct of animal experiments. Our
interest was to assess whether hLF, hLF
3N, and related
peptides display antimicrobial activity in vivo. For this purpose, a
well-established animal model for experimental thigh infections was
used (34, 35). In short, specific-pathogen-free male Swiss
mice weighing 20 to 25 g (Broekman Institute, Someren, The Netherlands)
were anesthetized with a single intraperitoneal injection of 0.1 ml of
saline containing 1 mg of fluanisone and 0.03 mg of fentanyl citrate
(Hypnorm; Janssen Pharmaceutics, Tilburg, The Netherlands). Immediately
thereafter, 107 CFU of antibiotic-resistant S. aureus or K. pneumoniae in 0.1 ml of saline was
injected into the right thigh muscle. At 24 h thereafter, 0.2 ml
of saline, containing various amounts of 99mTc-hLF or
radiolabeled peptides (0.3 to 30 µmol), was injected intravenously.
As controls, mice were injected with 0.2 ml of saline containing human
immunoglobulin G (IgG) (34, 35) or saline without any
peptide. At 24 h after injection of hLF or related peptides, the
mice were sacrificed by an intraperitoneal injection of 0.25 ml of
saline containing 12 mg of sodium pentobarbital (Sanofi BV, Div. Algin,
Maassluis, The Netherlands). Next, the infected thigh muscles were
removed and, after being weighed, homogenized in 4 ml of PBS.
Appropriate dilutions of the homogenates were applied to diagnostic
sensitivity test plates (Oxoid), and the number of colonies was
determined after an overnight culture at 37°C. Results are expressed
as the number of CFU per gram of infected tissue. All negative cultures
were assigned the value of 100 CFU/ml of homogenate, which is the lower
limit of detection.
Pharmacology.
The accumulation of proteins and peptides at
the site of infection, as well as the pharmacology of the radiolabeled
hLF preparations and related peptides in mice infected with
antibiotic-resistant S. aureus or K. pneumoniae,
was assessed by performing scintigraphy. The mice were placed in a
supine position on a planar gamma camera (GCA 7100/UI; Toshiba, Tokyo,
Japan) with both hind legs spread out and fixed with surgical tape.
Continuous whole-body acquisitions of every 60 s during the first
hour after injection of the tracer were made with the gamma camera,
equipped with a low-energy general-purpose parallel-hole collimator.
The camera was connected to a computer (GMS 5500 UI; Toshiba), and
high-resolution images of the animals were stored in a 256-by-256
matrix. The energy peak was set at 140 keV with a window of 20%. On
the scintigrams, anatomically adjusted regions of interest (ROI) were
drawn over the heart and both thighs, providing data about the
clearance of 99mTc-peptides and accumulation at the site of
infection. The clearance of 99mTc-labeled hLF or related
peptides from the circulation during the first hour after injection was
assessed by determining the half-life (t1/2) of
radioactivity in ROI drawn over the heart at various time intervals.
The amount of radioactivity in the heart was corrected for decay and
expressed as a percentage of injected dose (ID). Accumulation of hLF
and related peptides at the site of infection is expressed as the ratio
of the radioactivity counts in identical regions drawn over the
infected (target) and the noninfected thigh muscle (nontarget),
referred to below as the T/NT ratio (34, 35).
Statistical analysis.
Differences between the values for
hLF, hLF
3N, and bovine serum albumin, as well as for the
various hLF-related peptides and the negative control peptide, were
analyzed using the Mann-Whitney U test. The level of significance was
set at P < 0.05.
 |
RESULTS |
Antibacterial activity of hLF, hLF
3N, and related
synthetic peptides.
Based on the observation that the first
cationic domain of hLF is essential for its interaction with various
molecules, such as endotoxin and heparin (17, 32, 38), we
compared the antibacterial activity of hLF
3N and natural
hLF. The results revealed that both forms of hLF killed
antibiotic-resistant S. aureus (Fig.
1A), L. monocytogenes (Fig.
1B) and K. pneumoniae (results not shown) in a
dose-dependent fashion, with hLF being more potent (P < 0.05) than hLF
3N. In addition, natural hLF acted
faster (P < 0.05) than hLF
3N in killing
of these bacteria (Fig. 1C to E). In contrast, E. coli was
not killed by hLF or hLF
3N even at concentrations up to
12 µM (results not shown). To find which N-terminal amino acids of
hLF are essential for killing of bacteria, we determined the in
vitro bactericidal effects of synthetic peptides corresponding to the
first 11 N-terminal residues of hLF and fragments thereof against
various bacteria. The results revealed that hLF(1-11), hLF(2-11), and
hLF(3-11) displayed bactericidal activity against the various bacteria
whereas hLF(5-11) was ineffective (Fig.
2). Dose-response studies revealed that
hLF(1-11) and hLF(2-11) were considerably (P < 0.05)
more efficient than hLF(3-11) in killing of antibiotic-resistant
S. aureus (Fig. 2A), K. pneumoniae (Fig. 2C), and
E. coli (Fig. 2D) but not L. monocytogenes (Fig. 2B). In addition, hLF(4-11) killed L. monocytogenes (Fig.
2B), K. pneumoniae (Fig. 2C), and E. coli
(Fig. 2D) only at high concentrations but did not kill
antibiotic-resistant S. aureus (Fig. 2A). Together, these
data indicate that the first two arginines are essential for the
bactericidal activity of hLF against these bacteria. Next, we compared
the bactericidal activities of hLF(21-31), which includes the second
cationic domain of hLF and is known to display bactericidal activity
(22), and hLF(1-11) against antibiotic-resistant S. aureus, L. monocytogenes, K. pneumoniae, and E. coli.
The results revealed that hLF(1-11) is at least 10 times more
(P < 0.05) efficient than hLF(21-31) (Fig. 2).



View larger version (48K):
[in this window]
[in a new window]
|
FIG. 1.
Antibacterial activity of natural hLF and
hLF 3N against antibiotic-resistant S. aureus, L. monocytogenes, and K. pneumoniae. (A and B)
Dose-dependent reduction of the number of viable antibiotic-resistant
S. aureus (A) and L monocytogenes (B) cells by
natural hLF and hLF 3N. Approximately 1 × 106 to 2 × 106 CFU of bacteria was
exposed to different concentrations of natural hLF or
hLF 3N for 3 h at 37°C, and then the number of
viable bacteria was determined microbiologically. The detection limit
was 4,000 CFU. Results are means and standard deviations of at least
three separate experiments. (C to E) Time-dependent reduction of the
number of viable antibiotic-resistant S. aureus (C),
L. monocytogenes (D), and K. pneumoniae (E) by
natural hLF and hLF 3N. Approximately 1 × 106 to 2 × 106 CFU of bacteria was
exposed to 4 µM hLF or hLF 3N for various intervals at
37°C, and then the number of viable bacteria was determined
microbiologically. Results are means and standard deviations of at
least three separate experiments. *, P < 0.05
compared to bacteria exposed to bovine serum albumin; **,
P < 0.05 compared to bacteria exposed to 4 µM hLF.
|
|

View larger version (45K):
[in this window]
[in a new window]
|
FIG. 2.
Killing of antibiotic-resistant S. aureus
(A), L. monocytogenes (B), K. pneumoniae (C), and
E. coli (D) by hLF(1-11) as well as fragments thereof and
hLF(21-31). Approximately 2 × 106 CFU of the various
bacteria was exposed to various concentrations of hLF(1-11) or
fragments thereof or hLF(21-31) for 1 h at 37°C, and then the
number of viable bacteria was determined microbiologically. The
detection limit was 4,000 CFU. Results are means and standard
deviations of at least three separate experiments. In addition, the
effects of the peptides on the membrane permeability of the various
bacteria was assessed using 1 µg of PI/ml and FACS analysis. The
results, expressed as mean and standard deviation of the percentage of
PI-positive bacteria, are from at least three separate experiments.
|
|
Effect of natural hLF, hLF
3N, and related peptides on
the membrane permeability as well as the intracellular nonspecific
esterase activity of bacteria.
To gain insight into the mechanisms
underlying the antibacterial activity of hLF as well as related
peptides, we determined their effect on the membrane permeability of
bacteria. The results revealed that incubation of the various bacteria
with natural hLF (and hLF
3N) was not followed by a
significant change of the membrane permeability during the period of
analysis, i.e., 4 h after addition of these proteins. Based on
these results, we investigated the effects of natural hLF and
hLF
3N on the intracellular nonspecific esterase activity
of bacteria. We chose this enzyme because its activity correlates with
cell viability (31). The results revealed that hLF and
hLF
3N inhibited the intracellular nonspecific esterase
activity of antibiotic-resistant S. aureus, but not of
E. coli, within 1 to 2 h after addition of these
proteins (Fig. 3), suggesting that killing of bacteria by hLF (and hLF
3N) could be preceded
by intracellular effects in antibiotic-resistant S. aureus
without disruption of the membrane integrity. In agreement with this
possibility, we found that hLF, as well as hLF
3N, at
4°C did not affect the number of viable bacteria as well as the
nonspecific esterase activity whereas the defensin-like peptide
protegrin-1 (14, 25) did (results not shown). The protegrin-1 peptide kills bacteria through another mechanism, i.e.,
increasing the membrane permeability. In contrast to natural hLF and
hLF
3N, the various peptides, except hLF(5-11),
influenced the membrane permeability in a dose- and time-dependent
fashion (Fig. 2). When studied at concentrations that did not increase
the membrane permeability, these peptides did not affect the
nonspecific esterase activity of bacteria (results not shown).
Finally, dose-response studies revealed that hLF(1-11) was
considerably (P < 0.05) more efficient than hLF
(21-31) in increasing the membrane permeability of bacteria (Fig. 2).

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 3.
Effect of natural hLF, hLF 3N, and
protegrin-1 on nonspecific esterase activity of antibiotic-resistant
S. aureus. Approximately 2 × 106 CFU of
bacteria were incubated with 4 µM natural hLF or hLF 3N
in PBS-Tw for 2 h at 37°C and then incubated with 100 µM SFDA
in 20% (vol/vol) ethanol for 20 min at room temperature in the dark
and washed, and then the fluorescence intensity was measured by flow
cytometry. It should be realized that the formation of fluorescein
resulting from the degradation of SFDA by nonspecific esterase activity
is measured by FACS analysis. Consequently, low mean fluorescence
intensities indicate little esterase activity, provided that loss of
fluorescein due to an increased membrane permeability can be excluded
as an explanation. As controls, bacteria were exposed to 4 µM bovine
serum albumin (BSA) (negative control) for 2 h at 37°C or
protegrin-1 (positive control) for 30 min at 37°C instead of hLF of
hLF 3N. Results are from a representative experiment of
three independent experiments.
|
|
Antibacterial activity of natural hLF, hLF
3N, and
related peptides in experimental thigh muscle infections.
Within
24 h after injection of natural hLF, hLF
3N,
hLF(1-11), hLF(4-11), or hLF(21-31), the number of viable bacteria
in mice infected with antibiotic-resistant S. aureus was
reduced in a dose-dependent fashion; maximum effects were seen with 1 nmol of hLF, 10 nmol of hLF
3N, 0.1 nmol of hLF(1-11),
and 10 nmol of hLF(21-31) (Fig. 4). It should be noted that at the lowest level tested (0.1 nmol), the synthetic peptide hLF(1-11) resulted in approximately a
100-fold-higher reduction in the number of viable bacteria than did
natural hLF. The highest level of hLF(4-11) exerted some antibacterial
activity in mice infected with antibiotic-resistant S. aureus (Fig. 4). Similar results were found (2- to 3-log-unit
reduction) in mice infected with K. pneumoniae (results not
shown). Pharmacological studies revealed that natural hLF,
hLF
3N, hLF(1-11), and hLF(4-11), and hLF(21-31) were
rapidly removed from the circulation of these mice with mean
t1/2 values of approximately 19, 22, 9, 1, and 2 min, respectively (n = 3). Already within the first 1 min after injection of 1 nmol of radiolabeled natural hLF,
hLF
3N, hLF(1-11), hLF(4-11), or hLF(21-31) into
antibiotic-resistant S. aureus-infected mice, a significant
amount of radiolabeled peptide, i.e., approximately 1 to 1.5% of ID,
was observed at the site of infection. Moreover, the amount of
radiolabeled hLF or related peptide at the site of infection remained
constant during the period of analysis, i.e., the first 60 min after
injection of the radiolabeled protein or peptide (Fig.
5), indicating that natural hLF,
hLF
3N, and related peptides quickly reached and
accumulated at the site of infection.

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 4.
Bactericidal activity of natural hLF,
hLF 3N, and various related peptides in
antibiotic-resistant S. aureus-infected mice. Mice were
intramuscularly infected with approximately 107 CFU of
antibiotic-resistant S. aureus in 0.1 ml of saline, and
24 h later 0.2 ml of saline containing various amounts (range, 0.1 to 10 nmol) of natural hLF, hLF 3N, hLF(1-11),
hLF(4-11), or hLF(21-31) was injected intravenously. At 24 h
after injection of radiolabeled peptide the mice were killed by
intraperitoneal injection with sodium pentobarbital, and the thigh
muscle was removed, weighed, and then homogenized. Next, serial fold
dilutions of these homogenates were pipetted onto plates and the number
of CFU was determined microbiologically. It should be kept in mind that
hLF(1-11) is much more effective than natural hLF in eliminating
bacteria in mice with an experimental infection. Values are means and
standard deviations of CFU of antibiotic-resistant S. aureus
per gram of thigh muscle (n = 3 experiments; at least 3 mice in each experiment).
|
|

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 5.
Accumulation of 99mTc-hLF or related
peptides at the site of infection in mice experimentally infected with
antibiotic-resistant S. aureus. Accumulation of radiolabeled
hLF, hLF 3N, hLF(1-11), hLF(4-11), or hLF(21-31) and,
as a control, IgG at the site of infection in mice with an experimental
thigh muscle infection with antibiotic-resistant S. aureus
at various intervals after injection of radiolabeled protein or peptide
is represented by the ratio of the radioactivity counts in identical
ROI drawn over the infected (target, T) and the noninfected thigh
muscle (nontarget, NT). Results (T/NT ratios) are means and standard
deviations for at least three mice.
|
|
 |
DISCUSSION |
The main conclusion to be drawn from the present results is that
the N-terminal arginines 2 and 3 of hLF play an important role in its
bactericidal activity. This conclusion is based on the following
findings. First, the bactericidal activity of the physiologically
relevant truncated form hLF
3N (13, 15, 32),
i.e., hLF lacking the first 3 amino acids, was significantly lower than
that of natural hLF both in in vitro studies and in animals with an
experimental thigh muscle infection with antibiotic-resistant S. aureus (Fig. 4) or K. pneumoniae (results not shown).
It should be kept in mind that the amounts of hLF and
hLF
3N at the site of infection did not differ (Fig. 5),
excluding the possibility that differences in the bactericidal activity
of these proteins in mice can be attributed to differences in the
amount of protein at the site of infection. Second, comparison of the bactericidal activities of hLF(1-11) and peptides lacking one or more
of the first 5 residues revealed that the first 2 arginines are
essential for killing of bacteria. In agreement with these in vitro
data, we found that hLF(1-11) was much more effective than hLF(4-11)
in reducing the number of viable bacteria in antibiotic-resistant S. aureus-infected as well as K. pneumoniae-infected mice.
Our second conclusion pertains to mechanisms underlying the
bactericidal activity of hLF and related peptides. Natural hLF or
hLF
3N interacts with bacteria possibly through specific
binding sites (27), porins (9), endotoxin
(6, 32) or lipoteichoic acid (C. Ødegard, unpublished
data). Interaction of hLF and hLF
3N with bacteria
(35) inhibited the nonspecific esterase activity without
affecting their membrane permeability. These observations suggest that
hLF is taken up by bacteria, where it exerts its effects, such as
interaction with ATP (28) and/or mitochondria in
Candida albicans, as has recently been reported for histatin (11). These intracellular actions of hLF could result in
disruption of the metabolic activity and subsequently the death of the
bacteria. In agreement with this possibility, we found that at 4°C
hLF is not able to kill bacteria or to affect the nonspecific esterase activity of the bacteria whereas protegrin-1 can do so. These data
indicate that the bactericidal action of hLF requires metabolically active bacteria. The sequence of events initiated by synthetic peptides
derived from hLF and resulting in the death of the bacteria is
difficult to unravel because the bacteria are rapidly killed by these
peptides. For example, we could not establish conditions that allowed
us to measure the effects of hLF(1-11) and related peptides on the
nonspecific esterase activity of bacteria without affecting the
membrane permeability. Furthermore, for certain hLF-derived peptides,
e.g., hLF(21-31), no clear correlation between reduction of the number
of viable bacteria and the percentage of PI-positive bacteria was
found. This observation may indicate that enhanced membrane
permeability by antimicrobial peptides does not invariably lead to
bacterial cell death. Although we cannot draw a definitive conclusion
about the mechanisms underlying the bactericidal action of synthetic
hLF-derived peptides, it could be that the mechanisms differ between
synthetic peptides and natural peptides derived from the N terminus of
hLF. It should also be kept in mind that the size and tertiary
structure of the present synthetic peptides may differ considerably
from those of natural peptides derived from hLF. Moreover, it is highly
likely that potent bactericidal peptides are formed from natural hLF in
reponse to local conditions at sites where the bactericidal action is
required without exposing other anatomical localizations to the adverse
effects of these potent peptides. This feature could be an important
advantage of hLF when used to treat patients with infections.
A third striking finding in the present study is that hLF-derived
peptides are much more potent in mice with experimental infections with
bacteria than in in vitro assays for antibacterial activity. Possible
explanations for these findings include (i) synergism between hLF or
related peptides and other antimicrobial proteins/peptides, such as
lysozyme (16), or other local factors, such as pH and
Ca2+ and Zn2+ concentrations, and (ii)
interactions with host cells, leading to enhanced antibacterial
activities of the cells (20).
Other important findings in the present study concern the role of the
second cationic domain of hLF in its bactericidal activity. It has been
reported that peptides comprising the second cationic domain of hLF
display antibacterial activity (3). However, such a
peptide, i.e., hLF(21-31), was considerably less efficient in killing
of bacteria than hLF(1-11), which may suggest that the first cationic
domain contributes more than the second to killing of bacteria. In
agreement with this conclusion, we found that hLF(21-31) was less
effective than hLF(1-11) in reducing the number of viable bacteria in
the thigh muscle of mice infected with antibiotic-resistant S. aureus or K. pneumoniae.
Our observation that natural hLF is not bactericidal for E. coli O54 contrasts with earlier reports by others (7,
33) using different strains of E. coli. Although we
cannot offer a definitive explanation for this difference, technical
differences, e.g., the use of different E. coli strains,
impurity of hLF preparations, pH 2 treatment of the protein
(33), and the assay conditions (7), are
clearly important. In connection with the last suggestion, we noted
that in vitro hLF and hLF
3N displayed optimal
bactericidal activity when investigated in PBS-Tw whereas its
bactericidal activity in 10 mM sodium phosphate buffer supplemented
with 1% tryptase soya broth was rather poor (results not shown). Of
course, our in vitro observation that hLF and hLF
3N are
not able to kill E. coli does not exclude the posibility that this protein can be used to successfully treat infections with
this bacterium, as has recently been reported by others
(10).
Originally, these studies were designed to investigate whether hLF and
related peptides can be used to treat experimental infections with
bacteria, such as antibiotic-resistant S. aureus. It should
be realized that treatment of patients infected with antibiotic-resistant bacteria is an increasingly important problem in
hospitals. Currently, there are over 60,000 deaths per year in the
United States from hospital-acquired infections. Nearly 40% of
hospital-acquired infections with S. aureus are resistant to
all antibiotics except methicillin. A major finding in the present
structure-function analysis is that hLF(1-11) is highly effective
against infections with antibiotic (methicillin)-resistant S. aureus. It should be kept in mind that hLF(1-11) is much more effective than natural hLF in eliminating bacteria in mice with an
experimental infection. In addition, during the course of our experiments in mice, we noted that radiolabeled hLF and related peptides rapidly reached the site of infection and remained there throughout for the period of analysis (2 to 4 h). This prompted us
to compare the abilities of radiolabeled hLF and related peptides with
an established marker of infection or inflammation, i.e., radiolabeled
polyclonal human IgG (34, 35), to image of a bacterial
infection. The results clearly indicated that radiolabeled hLF and some
related peptides visualized the infection much faster than did
radiolabeled IgG and that in this respect hLF was superior to the
related peptides. The main drawback of radiolabeled hLF for imaging of
infections is its ability to bind to leukocytes (21, 26),
making this tracer unsuitable for discrimination between sterile
inflammatory processes and infectious sites.
 |
ACKNOWLEDGMENTS |
The secretarial assistance of M. H. Luijnenburg-Oostdam and
E. van Ballegoyen is greatly appreciated.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Infectious Diseases, C5-P, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands. Phone: 31 71 5262620. Fax: 31 71 5266758. E-mail: p.h.nibbering{at}lumc.nl.
Editor:
E. I. Tuomanen
 |
REFERENCES |
| 1.
|
Bellamy, W.,
M. Takase,
K. Yamauchi,
H. Wakabayashi,
K. Kawase, and M. Tomita.
1992.
Identification of the bactericidal domain of lactoferrin.
Biochim. Biophys. Acta
1121:130-136[CrossRef][Medline].
|
| 2.
|
Bullen, J. J.
1981.
The significance of iron in infection.
Rev. Infect. Dis.
3:1127-1138[Medline].
|
| 3.
|
Chapple, D. S.,
D. J. Mason,
C. L. Joannou,
E. W. Odell,
V. Gant, and R. W. Evans.
1998.
Structure-function relationship of antibacterial synthetic peptides homologous to a helical surface region on human lactoferrin against Escherichia coli serotype O111.
Infect. Immun.
66:2434-2440[Abstract/Free Full Text].
|
| 4.
|
de Koster, H. S.,
R. Amons,
W. E. Benckhuijsen,
M. Feijlbrief,
G. A. Schellekens, and J. W. Drijfhout.
1995.
The use of dedicated peptide libraries permits the discovery of high affinity binding peptides.
J. Immunol. Methods
197:179-188.
|
| 5.
|
Dionysius, D. A., and J. M. Milne.
1997.
Antibacterial peptides of bovine lactoferrin: purification and characterization.
J. Dairy Sci.
80:667-674[Abstract/Free Full Text].
|
| 6.
|
Elass-Rochard, E.,
A. Roseanu,
D. Legrand,
M. Trif,
V. Salmon,
C. Motas,
J. Montreuil, and G. Spik.
1995.
Lactoferrin-lipopolysaccharide interactions: involvement of the 28-34 loop region of human lactoferrin in the high affinity binding of Escherichia coli 055B5 lipopolysaccharide.
Biochem. J.
312:839-848.
|
| 7.
|
Ellison, R. T.,
T. J. Giehl, and M. M. LaForce.
1988.
Damage of the outer membrane of enteric gram-negative bacteria by lactoferrin and transferrin.
Infect. Immun.
56:2741-2781.
|
| 8.
|
Ellison, R. T., III.
1994.
The effects of lactoferrin on Gram-negative bacteria.
Adv. Exp. Med. Biol.
357:71-90[Medline].
|
| 9.
|
Erdei, J.,
A. Forsgren, and A. S. Naidu.
1994.
Lactoferrin binds to porins OmpF and OmpC in Escherichia coli.
Infect. Immun.
62:1236-1240[Abstract/Free Full Text].
|
| 10.
|
Haverson, L. A.,
I. Engberg,
L. Baltzer,
G. Dolphin,
L. A. Hanson, and I. Mattsby-Baltzer.
2000.
Human lactoferrin and peptides derived from a surface-exposed helical region reduce experimental Escherichia coli urinary tract infection in mice.
Infect. Immun.
68:5816-5823[Abstract/Free Full Text].
|
| 11.
|
Helmerhorst, E. J.,
P. Breeuwe,
W. van het Hof,
E. Walgreen,
L. C. J. M. Oomen,
E. C. I. Veerman,
A. van Nieuw Amerongen, and T. Abee.
1999.
The cellular target of histatin 5 on Candida albicans is the energized mitochondrion.
J. Biol. Chem.
274:7286-7291[Abstract/Free Full Text].
|
| 12.
|
Hoek, K. S.,
J. M. Milne,
P. A. Grieve,
D. A. Dionysius, and R. Smith.
1997.
Antibacterial activity of bovine lactoferrin-derived peptides.
Antimicrob. Agents Chemother.
41:54-59[Abstract].
|
| 13.
|
Hutchens, T. W.,
J. F. Henry, and T. T. Yip.
1991.
Structurally intact (78-kDa) form of maternal lactoferrin purified from urine of preterm infants fed human milk: identification of trypsin-like proteolytic cleavage event in vivo that does not result in fragment dissociation.
Proc. Natl. Acad. Sci. USA
15:2994-2998.
|
| 14.
|
Kokryakov, V. N.,
S. S. L. Harwig,
E. A. Panyutich,
A. A. Shevchenko,
G. M. Aleshina,
O. V. Shamova,
H. A. Korneva, and R. I. Lehrer.
1993.
Protegrins: leukocyte antimicrobial peptides that combine features of corticostatic defensins and tachyplesins.
FEBS Lett.
327:231-236[CrossRef][Medline].
|
| 15.
|
Legrand, D.,
P. H. van Berkel,
V. Salmon,
H. A. van Veen,
M. C. Slomianny,
J. H. Nuijens, and G. Spik.
1997.
The N-terminal Arg2, Arg3, Arg4 of human lactoferrin interact with sulphated molecules but not with the receptor present on Jurkat human lymphoblastic T-cells.
Biochem. J.
327:841-846.
|
| 16.
|
Leitch, E. C., and M. D. Wilcox.
1999.
Elucidation of the antistaphylococcal action of lactoferrin and lysozyme.
J. Med. Microbiol.
48:867-871[Abstract/Free Full Text].
|
| 17.
|
Mann, D. M.,
E. Romm, and M. Migliorini.
1994.
Delineation of the glycosaminoglycan-binding site in the human inflammatory response protein lactoferrin.
J. Biol. Chem.
269:23661-23667[Abstract/Free Full Text].
|
| 18.
|
Martin, E.,
T. Ganz, and R. I. Lehrer.
1995.
Defensins and other endogenous peptide antibiotics of vertebrates.
J. Leukoc. Biol.
58:128-137[Abstract].
|
| 19.
|
Mason, D. J.,
R. Dybowski,
J. W. Larrick, and V. A. Gant.
1997.
Antimicrobial action of rabbit leukocyte CAP18106-137.
Antimicrob. Agents Chemother.
41:624-629[Abstract].
|
| 20.
|
Myauchi, H.,
S. Hashimoto,
M. Nakajima,
I. Shinoda,
Y. Fukuwatari, and H. Hayasawa.
1998.
Bovine lactoferrin stimulates the phagocytic activity of human neutrophils: identification of its active domain.
Cell. Immunol.
187:34-37[CrossRef][Medline].
|
| 21.
|
Nuijens, J. H.,
P. H. C. van Berkel, and F. L. Schanbacher.
1996.
Structure and biological actions of lactoferrin.
J. Mammary Gland Biol. Neoplasia
1:285-295[CrossRef][Medline].
|
| 22.
|
Odell, E. W.,
R. Sarra,
M. Foxworthy,
D. S. Chapple, and R. W. Evans.
1996.
Antibacterial activity of peptides homologous to a loop region in human lactoferrin.
FEBS Lett.
382:175-178[CrossRef][Medline].
|
| 23.
|
Pauwels, E. K. J.,
M. M. Welling,
R. I. J. Feitsma,
D. E. Atsma, and W. Nieuwenhuizen.
1993.
The labelling of proteins and LDL with 99mTc: a new direct method employing KBH4 and stannous chloride.
Nucl. Med. Biol.
20:825-833[CrossRef][Medline].
|
| 24.
|
Perez-Playa, E.,
R. A. Houghton, and S. E. Blondelle.
1995.
The role of amphipathicity in the folding, self-association, and biological activity of multiple subunit small proteins.
J. Biol. Chem.
270:1048-1056[Abstract/Free Full Text].
|
| 25.
|
Qu, X.-D.,
S. S. L. Harwig,
A. Oren,
W. H. Schafer, and R. I. Lehrer.
1996.
Susceptibility of Neisseria gonorrhoeae to protegrins.
Infect. Immun.
64:1240-1245[Abstract].
|
| 26.
|
Sanchez, L,
M. Calvo, and J. H. Brock.
1992.
Biological role of lactoferrin.
Arch. Dis. Child.
67:657-661[Free Full Text].
|
| 27.
|
Schrijvers, A.,
R. Bonnah,
H. Wong, and M. Retzer.
1998.
Bacterial lactoferrin receptors.
Adv. Exp. Med. Biol.
443:123-133[Medline].
|
| 28.
|
Semenov, D. V,
T. G. Kanyshkova,
A. M. Akimzhanov,
V. N. Buneva, and G. A. Nevinsky.
1998.
Interaction of human milk lactoferrin with ATP.
Biochemistry (Moscow)
63:944-951.
|
| 29.
|
Shai, Y.
1999.
Mechanism of the binding, insertion, and destabilization of phospholipid bilayer membranes by -helical antimicrobial and cell non-selective membrane-lytic peptides.
Biochim. Biophys. Acta
1462:55-70[Medline].
|
| 30.
|
Tomita, M.,
W. Bellamy,
M. Takase,
K. Yamauchi,
H. Wakabayashi, and K. Kawase.
1991.
Potent antibacterial peptides generated by pepsin digestion of bovine lactoferrin.
J. Dairy Sci.
74:4137-4142[Abstract].
|
| 31.
|
Tsuji, T.,
Y. Kawasaki,
S. Takeshima,
T. Sekiya, and S. Tanaka.
1995.
A new fluorescence staining assay for visualizing living micro-organisms in soil.
Appl. Environ. Microbiol.
61:3415-3421[Abstract].
|
| 32.
|
van Berkel, P. H. C.,
M. E. J. Geerts,
H. A. van Veen,
M. Mericskay,
H. A. de Boer, and J. H. Nuijens.
1997.
N-terminal stretch Arg2, Arg3, Arg4, and Arg5 of human lactoferrin is essential for binding to heparin, bacterial lipopolysaccharide, human lysozyme and DNA.
Biochem. J.
328:145-151.
|
| 33.
|
Ward, P. P.,
C. S. Piddington,
G. A. Cunningham,
X. Zhou,
R. D. Wyatt, and O. M. Conneely.
1995.
A system for production of commercial quantities of human lactoferrin: a broad spectrum natural antibiotic.
Bio/Technology
13:498-503[CrossRef][Medline].
|
| 34.
|
Welling, M. M.,
P. S. Hiemstra,
M. T. van den Barselaar,
A. Paulusma-Annema,
P. H. Nibbering,
E. K. J. Pauwels, and W. Calame.
1998.
Antibacterial activity of human neutrophil defensins in experimental infections in mice is accompanied by increased leukocyte accumulation.
J. Clin. Investig.
8:1583-1589.
|
| 35.
|
Welling, M. M.,
A. Paulusma-Annema,
E. K. J. Pauwels, and P. H. Nibbering.
2000.
99mTechnetium labelled antimicrobial peptides that discriminate between bacterial infections and sterile inflammations.
Eur. J. Nucl. Med.
27:292-301[CrossRef][Medline].
|
| 36.
|
Wu, H. D.,
M. Monroe, and F. C. Church.
1995.
Characterization of the glycosaminoglycan-binding region of lactoferrin.
Arch. Biochem. Biophys.
317:85-92[CrossRef][Medline].
|
| 37.
|
Yamauchi, K.,
M. Tomita,
T. J. Giehl, and R. T. Ellison.
1993.
Antibacterial activity of lactoferrin and a pepsin-derived lactoferrin peptide fragment.
Infect. Immun.
61:719-728[Abstract/Free Full Text].
|
| 38.
|
Zhang, G. H.,
D. M. Mann, and C. M. Tsai.
1999.
Neutralization of endotoxin in vitro and in vivo by a human lactoferrin-derived peptide.
Infect. Immun.
67:1353-1358[Abstract/Free Full Text].
|
Infection and Immunity, March 2001, p. 1469-1476, Vol. 69, No. 3
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.3.1469-1476.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
van der Plas, M. J. A., Jukema, G. N., Wai, S.-W., Dogterom-Ballering, H. C. M., Lagendijk, E. L., van Gulpen, C., van Dissel, J. T., Bloemberg, G. V., Nibbering, P. H.
(2008). Maggot excretions/secretions are differentially effective against biofilms of Staphylococcus aureus and Pseudomonas aeruginosa. J Antimicrob Chemother
61: 117-122
[Abstract]
[Full Text]
-
Saidi, H., Eslaphazir, J., Carbonneil, C., Carthagena, L., Requena, M., Nassreddine, N., Belec, L.
(2006). Differential Modulation of Human Lactoferrin Activity against Both R5 and X4-HIV-1 Adsorption on Epithelial Cells and Dendritic Cells by Natural Antibodies. J. Immunol.
177: 5540-5549
[Abstract]
[Full Text]
-
Zhu, H., Hart, C. A., Sales, D., Roberts, N. B.
(2006). Bacterial killing in gastric juice - effect of pH and pepsin on Escherichia coli and Helicobacter pylori.. J Med Microbiol
55: 1265-1270
[Abstract]
[Full Text]
-
Jenssen, H., Hamill, P., Hancock, R. E. W.
(2006). Peptide Antimicrobial Agents. Clin. Microbiol. Rev.
19: 491-511
[Abstract]
[Full Text]
-
Lee, H.-Y., Park, J.-H., Seok, S.-H., Baek, M.-W., Kim, D.-J., Lee, B.-H., Kang, P.-D., Kim, Y.-S., Park, J.-H.
(2005). Potential antimicrobial effects of human lactoferrin against oral infection with Listeria monocytogenes in mice. J Med Microbiol
54: 1049-1054
[Abstract]
[Full Text]
-
Viejo-Diaz, M., Andres, M. T., Fierro, J. F.
(2005). Different Anti-Candida Activities of Two Human Lactoferrin-Derived Peptides, Lfpep and Kaliocin-1. Antimicrob. Agents Chemother.
49: 2583-2588
[Abstract]
[Full Text]
-
Faber, C., Stallmann, H. P., Lyaruu, D. M., Joosten, U., von Eiff, C., van Nieuw Amerongen, A., Wuisman, P. I. J. M.
(2005). Comparable Efficacies of the Antimicrobial Peptide Human Lactoferrin 1-11 and Gentamicin in a Chronic Methicillin-Resistant Staphylococcus aureus Osteomyelitis Model. Antimicrob. Agents Chemother.
49: 2438-2444
[Abstract]
[Full Text]
-
Dijkshoorn, L., Brouwer, C. P. J. M., Bogaards, S. J. P., Nemec, A., van den Broek, P. J., Nibbering, P. H.
(2004). The Synthetic N-Terminal Peptide of Human Lactoferrin, hLF(1-11), Is Highly Effective against Experimental Infection Caused by Multidrug-Resistant Acinetobacter baumannii. Antimicrob. Agents Chemother.
48: 4919-4921
[Abstract]
[Full Text]
-
Faber, C., Hoogendoorn, R. J. W., Stallmann, H. P., Lyaruu, D. M., van Nieuw Amerongen, A., Wuisman, P. I. J. M., on behalf of STEGA (Skeletal Tissue Engineering Gr,
(2004). In vivo comparison of Dhvar-5 and gentamicin in an MRSA osteomyelitis prevention model. J Antimicrob Chemother
54: 1078-1084
[Abstract]
[Full Text]
-
Stallmann, H. P., Faber, C., Bronckers, A. L. J. J., Nieuw Amerongen, A. V., Wuisman, P. I. J. M.
(2004). Osteomyelitis prevention in rabbits using antimicrobial peptide hLF1-11- or gentamicin-containing calcium phosphate cement. J Antimicrob Chemother
54: 472-476
[Abstract]
[Full Text]
-
Nibbering, P. H., Welling, M. M., Paulusma-Annema, A., Brouwer, C. P.J.M., Lupetti, A., Pauwels, E. K.J.
(2004). 99mTc-Labeled UBI 29-41 Peptide for Monitoring the Efficacy of Antibacterial Agents in Mice Infected with Staphylococcus aureus. JNM
45: 321-326
[Abstract]
[Full Text]
-
Stallmann, H. P., Faber, C., Slotema, E. T., Lyaruu, D. M., Bronckers, A. L. J. J., Amerongen, A. V. N., Wuisman, P. I. J. M.
(2003). Continuous-release or burst-release of the antimicrobial peptide human lactoferrin 1-11 (hLF1-11) from calcium phosphate bone substitutes. J Antimicrob Chemother
52: 853-855
[Abstract]
[Full Text]
-
Kerr, D. E., Wellnitz, O.
(2003). Mammary expression of new genes to combat mastitis. J ANIM SCI
81: 38-47
[Abstract]
[Full Text]
-
Lupetti, A., Paulusma-Annema, A., Welling, M. M., Dogterom-Ballering, H., Brouwer, C. P. J. M., Senesi, S., van Dissel, J. T., Nibbering, P. H.
(2003). Synergistic Activity of the N-Terminal Peptide of Human Lactoferrin and Fluconazole against Candida Species. Antimicrob. Agents Chemother.
47: 262-267
[Abstract]
[Full Text]
-
Teng, C. T., Beard, C., Gladwell, W.
(2002). Differential Expression and Estrogen Response of Lactoferrin Gene in the Female Reproductive Tract of Mouse, Rat, and Hamster. Biol. Reprod.
67: 1439-1449
[Abstract]
[Full Text]
-
Lupetti, A., Paulusma-Annema, A., Senesi, S., Campa, M., van Dissel, J. T., Nibbering, P. H.
(2002). Internal Thiols and Reactive Oxygen Species in Candidacidal Activity Exerted by an N-Terminal Peptide of Human Lactoferrin. Antimicrob. Agents Chemother.
46: 1634-1639
[Abstract]
[Full Text]
-
Edde, L., Hipolito, R. B., Hwang, F. F. Y., Headon, D. R., Shalwitz, R. A., Sherman, M. P.
(2001). Lactoferrin protects neonatal rats from gut-related systemic infection. Am. J. Physiol. Gastrointest. Liver Physiol.
281: G1140-G1150
[Abstract]
[Full Text]